GoKawiilNovartis Halts Eight Trials of Experimental Autoimmune Cell Therapy After Patient Deaths
Novartis suspended eight clinical trials testing a cell therapy for autoimmune and neurological conditions after three participants died in late August. The company has not disclosed the cause of death or which specific therapy is affected beyond confirming the pause across all related studies.
GoKawiil's interpretation of the reporting above, not reported fact.
Cell therapies like CAR-T are increasingly being explored beyond cancer for autoimmune diseases, and safety setbacks like this could slow regulatory and investor enthusiasm for the approach. The outcome of Novartis's investigation will likely influence how other companies pursuing similar therapies proceed with trial design and patient monitoring.
- Novartis paused eight trials of an experimental autoimmune/neurological cell therapy.
- Three patient deaths triggered the suspension in late August.
- The pause could affect broader confidence in cell therapies for non-cancer indications.
Source: wsj.com, 2026-09-01
Published there as: “Novartis Pauses Autoimmune Cell Therapy Studies After Deaths”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.